Disease · MONDO_0001220

hypoparathyroidism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypoparathyroidism. Diseases, record MONDO_0001220. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001220

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypoparathyroidism; Open Targets
Open Targets ID: MONDO_0001220; Open Targets
Other names: Decreased parathyroid hormone secretion, Low parathyroid hormone; Open Targets
Disease Ontology: DOID:11199; Disease Ontology
MeSH: D007011; MeSH
NCI Thesaurus: C78350; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 17 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, FDA and TTD; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PARATHYROID HORMONE	CHEMBL2108078	Protein	Approval	DailyMed and EMA Human Drugs	21	19	17	Drugs and targets
PALOPEGTERIPARATIDE	CHEMBL5095475	Protein	Approval	ClinicalTrials.gov, EMA Human Drugs and FDA	7	4	4	Drugs and targets
ERGOCALCIFEROL	CHEMBL1536	Small molecule	Approval	DailyMed and TTD	5	1	1	Drugs and targets
CALCITRIOL	CHEMBL846	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
ENEBOPARATIDE	CHEMBL5095311	Protein	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
CALCIUM CARBONATE	CHEMBL1200539	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ENCALERET	CHEMBL1672973	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TERIPARATIDE	CHEMBL525610	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOSPORINE	CHEMBL160	Protein	Phase 1/2	ClinicalTrials.gov	2	2	2	Drugs and targets
DACLIZUMAB	CHEMBL1201605	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	3	Parathyroid hormone receptor agonist	Approval	https://conductscience.org/library/genes/5745	Drugs and targets
VDR	Vitamin D3 receptor	3	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 1/2	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1/2	https://conductscience.org/library/genes/2280	Drugs and targets
IL2RA	Interleukin-2 receptor	1	Interleukin-2 receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3559	Drugs and targets
IL2RB	Interleukin-2 receptor	1	Interleukin-2 receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	Interleukin-2 receptor	1	Interleukin-2 receptor inhibitor	Phase 1/2	https://conductscience.org/library/genes/3561	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 1/2	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 1/2	https://conductscience.org/library/genes/3615	Drugs and targets
PPIA	Peptidyl-prolyl cis-trans isomerase A	1	Cyclophilin A modulator	Phase 1/2	https://conductscience.org/library/genes/5478	Drugs and targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00478569	Adherence to PTH(1-84) Treatment (FP-002-IM)		1,179	2014-05-28	Clinical Use of PTH(1-84)	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT05239221	AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism	Phase 1/2	132	2024-01-31	Chronic Hypoparathyroidism	ENEBOPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT00732615	Use of NPSP558 in the Treatment of Hypoparathyroidism	Phase 3	124	2015-03-06	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT03324880	A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)	Phase 4	93	2023-06-09	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT04701203	A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism	Phase 3	84	2025-02-28	Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases	PALOPEGTERIPARATIDE	Its record names the disease	ClinicalTrials.gov
NCT00473265	Bone Properties in Hypoparathyroidism: Effects of PTH	Phase 2/3	68	2015-07-16	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT01199614	HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism	Phase 3	62	2024-07-05	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT01297309	A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)	Phase 3	51	2019-08-06	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT01268098	Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)	Phase 3	42	2015-03-06	Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT02910466	A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism	Phase 4	39	2021-07-28	Chronic Hypoparathyroidism, Hypoparathyroidism	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
NPSP558 vs Placebo: serious adverse events	9 of 84	4 of 40	124	NCT00732615	Trial comparisons
rhPTH (1-84) vs Placebo: deaths from any cause	0 of 45	0 of 48	93	NCT03324880	Trial comparisons
rhPTH (1-84) vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)	41 of 45	46 of 48	93	NCT03324880	Trial comparisons
rhPTH (1-84) vs Placebo: serious adverse events	6 of 45	6 of 48	93	NCT03324880	Trial comparisons
rhPTH (1-84) vs Placebo: Number of Participants Who Achieve Composite Criteria for Albumin-corrected Serum Calcium Concentration, Active Vitamin D Dose and Oral Elemental Calcium Supplement Dose at Week 26	21 of 40	6 of 47	87	NCT03324880	Trial comparisons
rhPTH (1-84) vs Placebo: Number of Participants With Response at Week 26 [Early Termination (ET)]	25 of 32	24 of 38	70	NCT03324880	Trial comparisons
NPSP558 - 25 µg Dose vs NPSP558 - 50 µg Dose: serious adverse events	0 of 19	0 of 23	42	NCT01268098	Trial comparisons
PTH 1-34 vs Calcitriol & Calcium: serious adverse events	0 of 14	0 of 13	27	NCT00001304	Trial comparisons
Teriparatide vs Control: serious adverse events	0 of 5	0 of 5	10	NCT01171690	Trial comparisons

Papers from its trials29

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26684150	RESULT	1	PubMed
23607606	RESULT	1	PubMed
20236866	RESULT	2	PubMed
19066739	RESULT	2	PubMed
18557726	RESULT	2	PubMed
18424759	RESULT	2	PubMed
18035553	RESULT	2	PubMed
17284531	RESULT	1	PubMed
15100156	RESULT	1	PubMed
41847596	DERIVED	1	PubMed

1 to 10 of 29

See all 29 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001220

GET https://conductscience.org/api/diseases/v1/MONDO_0001220/trials?page=2

API reference For AI assistants